Verastem Inc (NASDAQ:VSTM) traded down 5.4% on Thursday after Zacks Investment Research downgraded the stock from a hold rating to a sell rating. The stock traded as low as $3.15 and last traded at $3.17. 3,763,545 shares changed hands during trading, an increase of 52% from the average session volume of 2,478,497 shares. The stock had previously closed at $3.35.
VSTM has been the subject of a number of other reports. ValuEngine cut Verastem from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. Raymond James dropped their price target on Verastem from $12.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday. BidaskClub upgraded Verastem from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target (down from $13.00) on shares of Verastem in a research note on Thursday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $12.97.
A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in Verastem by 21.0% during the 4th quarter. BlackRock Inc. now owns 5,621,011 shares of the biopharmaceutical company’s stock worth $18,886,000 after purchasing an additional 976,123 shares during the last quarter. Vanguard Group Inc. raised its position in Verastem by 20.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,130,491 shares of the biopharmaceutical company’s stock worth $22,696,000 after purchasing an additional 532,484 shares during the last quarter. Vanguard Group Inc raised its position in Verastem by 20.5% during the 3rd quarter. Vanguard Group Inc now owns 3,130,491 shares of the biopharmaceutical company’s stock worth $22,696,000 after purchasing an additional 532,484 shares during the last quarter. Millennium Management LLC raised its position in Verastem by 2,376.5% during the 4th quarter. Millennium Management LLC now owns 1,248,037 shares of the biopharmaceutical company’s stock worth $4,193,000 after purchasing an additional 1,197,642 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in Verastem by 1,540.3% during the 4th quarter. Two Sigma Investments LP now owns 1,235,176 shares of the biopharmaceutical company’s stock worth $4,150,000 after purchasing an additional 1,159,874 shares during the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.
The stock has a market capitalization of $239.08 million, a PE ratio of -2.31 and a beta of 3.04. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.97 and a quick ratio of 2.97.
Verastem (NASDAQ:VSTM) last announced its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.23. The company had revenue of $1.21 million for the quarter, compared to the consensus estimate of $5.56 million. Equities analysts predict that Verastem Inc will post -1.95 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Verastem (VSTM) Stock Price Down 5.4% on Analyst Downgrade” was reported by Macon Daily and is the property of of Macon Daily. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://macondaily.com/2019/03/14/verastem-vstm-stock-price-down-5-4-on-analyst-downgrade.html.
About Verastem (NASDAQ:VSTM)
Verastem, Inc, operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Recommended Story: Discover Your Risk Tolerance
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.